Report Feature
Cholesterol-Lowering Drug Trends and Forecast
The future of the global cholesterol-lowering drug market looks promising with opportunities in the cardiovascular diseases, hypercholesterolemia, and hyperlipidemia markets. The global cholesterol-lowering drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030. The major drivers for this market are rise in tobacco and alcohol intake, rising awareness regarding bad cholesterol among people, and increasing elderly population facing cholesterol-related issues.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Cholesterol-Lowering Drug by Segment
The study includes a forecast for the global cholesterol-lowering drug by disease type, class of drug, distribution channels, and region.Cholesterol-Lowering Drug Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:
• Cardiovascular Diseases
• Hypercholesterolemia
• Hyperlipidemia
Cholesterol-Lowering Drug Market by Class of Drug [Shipment Analysis by Value from 2018 to 2030]:
• Cholesterol Absorption Inhibitors
• Fibrates
• Fixed-Dose Combinations
• Ion Exchange Resins
• Novel Cholesterol-Lowering Drugs
• PCSK9 Inhibitors
• Statins
Cholesterol-Lowering Drug Market by Distribution Channels [Shipment Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
Cholesterol-Lowering Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Cholesterol-Lowering Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cholesterol-lowering drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cholesterol-lowering drug companies profiled in this report include-• Kowa
• Amgen
• AstraZeneca
• Clinical Reference Laboratory
• Novartis
• Cell Biolabs
• Merck
• LabCorp
• Daiichi Sankyo
• Pfizer
Cholesterol-Lowering Drug Market Insights
Lucintel forecasts that statin is expected to witness the highest growth over the forecast period due to introduction of successful treatments such as PCSK9 inhibitors and bempedoic acid. Within this market, cardiovascular diseases is expected to witness the highest growth. North America is expected to witness highest growth over the forecast period due to rise in heart ailments, substantial investments in the healthcare sector, and changes in lifestyle.Features of the Global Cholesterol-Lowering Drug Market
Market Size Estimates: Cholesterol-lowering drug market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions. Segmentation Analysis: Cholesterol-lowering drug market size by disease type, class of drug, distribution channels, and region in terms of value ($B). Regional Analysis: Cholesterol-lowering drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different disease type, class of drug, distribution channels, and regions for the cholesterol-lowering drug market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cholesterol-lowering drug market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.FAQ
Q1. What is the growth forecast for cholesterol-lowering drug market? Answer: The global cholesterol-lowering drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030. Q2. What are the major drivers influencing the growth of the cholesterol-lowering drug market? Answer: The major drivers for this market are rise in tobacco and alcohol intake, rising awareness regarding bad cholesterol among people, and increasing elderly population facing cholesterol-related issues. Q3. What are the major segments for cholesterol-lowering drug market? Answer: The future of the global cholesterol-lowering drug market looks promising with opportunities in the cardiovascular diseases, hypercholesterolemia, and hyperlipidemia markets. Q4. Who are the key cholesterol-lowering drug market companies? Answer: Some of the key cholesterol-lowering drug companies are as follows:• Kowa
• Amgen
• AstraZeneca
• Clinical Reference Laboratory
• Novartis
• Cell Biolabs
• Merck
• LabCorp
• Daiichi Sankyo
• Pfizer Q5. Which cholesterol-lowering drug market segment will be the largest in future? Answer: Lucintel forecasts that statin is expected to witness the highest growth over the forecast period due to introduction of successful treatments such as PCSK9 inhibitors and bempedoic acid. Q6. In cholesterol-lowering drug market, which region is expected to be the largest in next 5 years? Answer: North America is expected to witness highest growth over the forecast period due to rise in heart ailments, substantial investments in the healthcare sector, and changes in lifestyle. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.
Table of Contents
1. Executive Summary
6.2 Emerging Trends in the Global Cholesterol-Lowering Drug Market
4.1 Global Cholesterol-Lowering Drug Market by Region
4.2.1 North American Cholesterol-Lowering Drug Market by Disease Type: Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia
4.2.2 North American Cholesterol-Lowering Drug Market by Class of Drug: Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins
4.3.1 European Cholesterol-Lowering Drug Market by Disease Type: Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia
4.3.2 European Cholesterol-Lowering Drug Market by Class of Drug: Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins
4.4.1 APAC Cholesterol-Lowering Drug Market by Disease Type: Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia
4.4.2 APAC Cholesterol-Lowering Drug Market by Class of Drug: Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins
4.5.1 ROW Cholesterol-Lowering Drug Market by Disease Type: Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia
4.5.2 ROW Cholesterol-Lowering Drug Market by Class of Drug: Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins
6.1.1 Growth Opportunities for the Global Cholesterol-Lowering Drug Market by Disease Type
6.1.2 Growth Opportunities for the Global Cholesterol-Lowering Drug Market by Class of Drug
6.1.3 Growth Opportunities for the Global Cholesterol-Lowering Drug Market by Distribution Channels
6.1.4 Growth Opportunities for the Global Cholesterol-Lowering Drug Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
Key Questions
- • What are some of the most promising, high-growth opportunities for the cholesterol-lowering drug market by disease type (cardiovascular diseases, hypercholesterolemia, and hyperlipidemia), class of drug (cholesterol absorption inhibitors, fibrates, fixed-dose combinations, ion exchange resins, novel cholesterol-lowering drugs, PCSK9 inhibitors, and statins), distribution channels (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- • Which segments will grow at a faster pace and why?
- • Which region will grow at a faster pace and why?
- • What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- • What are the business risks and competitive threats in this market?
- • What are the emerging trends in this market and the reasons behind them?
- • What are some of the changing demands of customers in the market?
- • What are the new developments in the market? Which companies are leading these developments?
- • Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- • What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- • What M&A activity has occurred in the last 5 years and what has its impact been on the industry? For any questions related to Cholesterol-Lowering Drug Market, Cholesterol-Lowering Drug Market Size, Cholesterol-Lowering Drug Market Growth, Cholesterol-Lowering Drug Market Analysis, Cholesterol-Lowering Drug Market Report, Cholesterol-Lowering Drug Market Share, Cholesterol-Lowering Drug Market Trends, Cholesterol-Lowering Drug Market Forecast, Cholesterol-Lowering Drug Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
